Medical Dynamics

Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration (PR Newswire)

Pfizer To Sell Viagra In Israel Via Internet (Globe Newswire)

Inovio Biomedical Cervical Cancer Therapeutic Vaccine Generates Dose-Related Immune Response in Clinical Trial (BusinessWire)

Vertex Remains On Track With Telaprevir For 2010 NDA, 2011 Anticipated Launch (Health News Daily)

Read the rest of this entry »

• Glaxo to Close Italy R&D Center, Affecting 500 Jobs, Unions Say (Bloomberg)
• QIAGEN Unit and Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients (MarketWatch)
• PREVIEW-Sanofi Q4 Seen Up, Cautious for 2010 (Reuters)
• EC Changes on Running Pharma Must Not be Cosmetic – DTB (PharmaTimes)

Read the rest of this entry »

• Glaxo Plans More Savings as Flu Windfall Dwindles (Reuters)
• Pfizer Misses Estimates, and Shares Slide (The New York Times)
• Allergan 4Q Profit Rises 51%; Sees Weak 1Q Earnings (The Wall Street Journal)
• EU “Pushing” India Over Generics in “Secret” Trade Talks (PharmaTimes)

Read the rest of this entry »

• Pfizer profit misses; 2010 outlook below Street (Reuters)
• Now It’s Actavis vs Teva in Fight for Ratiopharm – Report (PharmaTimes)
• Roche FY Net Profit Down 22 Percent on Genentech Costs (PharmaLive)
• FDA Requests $4.03 Billion to Promote and Protect Public Health (World Pharma News)

Read the rest of this entry »

• Obama Budget Includes $38M from Generics User Fees (PharmaTimes)
• Reports: Glaxo to Cut Thousands of Jobs (Reuters)
• Sanofi-Aventis Plans to Set up Healthcare JV in China (TradingMarkets)
• FDA Issues Liver Risk Warning For Bristol-Myers HIV Drug (WITN)

Read the rest of this entry »

• Pfizer: Expects to be No.1 in Japan Generic Drugs (Reuters)
• Drug giants seek help to cut costs (PharmacyEurope)
• AstraZeneca to Cut 8000 Pharmaceutical Jobs (Pharmaceutical Jobs)
• GSK Silent on Job Cut Rumors, New Tykerb OK (PharmaTimes)

Read the rest of this entry »

• EU Generics Makers Demand “Clear, Open Market” (PharmaTimes)
• Sanofi-aventis, Minsheng Pharma Ink Deals to Form New Consumer Healthcare JV – Quick Facts (RTT News)
• Philippines to Announce Second Drug Price-Cut List (Bloomberg)
• AstraZeneca Cuts 8,000 jobs, No Big M&A Planned (PharmaTimes)

Read the rest of this entry »

• AZ Posts 23% Rise in 2009 Core Profit (PharmaTimes)
• P&G’s Product and Stock Prices Take Stage (The Wall Street Journal)
• Merck Granted European Approval for New Fertility Treatment ELONVA (TradingMarkets)
• EMA Calls for Opinions on its Road Map 2015 (PharmaTimes)

Read the rest of this entry »

• Novartis Profits Soar as Vasella Steps Down as CEO (PharmaTimes)
• MHRA Warns Of Internet Sales Of Counterfeit Alli (Pharmaceutical Business Review)
• Novartis Incoming CFO: No Plan For New Cost-Cutting Program (The Wall Street Journal)
• Bristol-Myers Squibb announces EU approval of ORENCIA (Zenopa)

Read the rest of this entry »

• China Agrees to Open Up Market for Indian Drugmakers (PharmaTimes)
• A Fibromyalgia Drug That Improves Sleep Quality More Than Pfizer’s Lyrica Would Earn Sizeable Patient Share in the U.S. and Europe (PR Newswire)
• Alcon Investor Expects Novartis to Raise Offer (Reuters)
• EMA’s First “compassionate use” Opinion is for Tamiflu (PharmaTimes)

Read the rest of this entry »